Ovarian cancer transformation from adenocarcinoma to undifferentiated small cell carcinoma: A case report
- PMID: 26137046
- PMCID: PMC4467345
- DOI: 10.3892/ol.2015.3031
Ovarian cancer transformation from adenocarcinoma to undifferentiated small cell carcinoma: A case report
Abstract
The ovaries contain cells that have the capacity for regeneration and cancer stem cells (CSC) that are capable of differentiating aberrantly from the homeostatic controls. The histology of ovarian cancer does not usually change in a patient. However, CSCs are the origin of a number of tumors. CSCs are known to exist in ovarian carcinomas and the expression of CD44, c-Kit and CD133 has been identified in such carcinomas. This study presents the case of a patient diagnosed with ovarian cancer with an abdominal mass who underwent surgery, eight cycles of gemcitabine-paclitaxel chemotherapy and irradiation. Pathological examination indicated a transformation from adenocarcinoma to undifferentiated small cell carcinoma. The expression of CD133 changed from negative to positive in ovarian carcinomas. The present case indicates that any histological changes observed in ovarian neoplasms originate from neoplastic stem cells. In addition, this case demonstrates the importance of repeatedly assessing therapy by tumor biopsy throughout the course of ovarian cancer treatment.
Keywords: adenocarcinoma; ovarian cancer; undifferentiated small cell carcinoma.
Figures





Similar articles
-
Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors.J Ovarian Res. 2018 Aug 18;11(1):69. doi: 10.1186/s13048-018-0439-3. J Ovarian Res. 2018. PMID: 30121075 Free PMC article.
-
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16. Eur J Cancer. 2017. PMID: 28525846
-
Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.Stem Cell Res Ther. 2015 Dec 30;6:262. doi: 10.1186/s13287-015-0249-0. Stem Cell Res Ther. 2015. PMID: 26718286 Free PMC article.
-
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.J Cell Biochem. 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. J Cell Biochem. 2013. PMID: 22887554 Review.
-
From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.Adv Anat Pathol. 2007 May;14(3):149-77. doi: 10.1097/PAP.0b013e3180504abf. Adv Anat Pathol. 2007. PMID: 17452813 Review.
Cited by
-
Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.Front Oncol. 2022 Feb 25;12:778545. doi: 10.3389/fonc.2022.778545. eCollection 2022. Front Oncol. 2022. PMID: 35280757 Free PMC article.
References
-
- Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65:3025–3029. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous